Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 8 | Vintage Vibes

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Why Sanofi Shares Are Trading Lower Today

Why Sanofi Shares Are Trading Lower Today

Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer,

DRIO: Future Brightens with $40M Raise & Sanofi Deal

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

Sanofi SA (NASDAQ:SNY) has signed a collaboration with Adagene Inc (NASDAQ:ADAG) to advance two preclinical immuno-oncology candidates and an option to develop two more. Sanofi is paying $17.5 million upfront and promising up to $2.5 billion in potential milestones. Under the terms of the agreement, Adagene will be responsible for early-stage research activities to develop…

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi

Here's a roundup of top developments in the biotech space over the last 24 hours.

3 Unstoppable Healthcare Stocks to Buy and Hold in 2022

The healthcare industry has ridden a promising wave of innovation and investments over the past few years. Also, with continuing acceleration in the digital transformation of healthcare and breakthrough developments, with healthcare expenditure expected to grow in the coming years, the industry’s prospects look bright. Therefore, we think healthcare stocks…

France's Sanofi to seek Covid vaccine approval after months of delays

French pharmaceuticals giant Sanofi has said that its Covid-19 vaccine, developed with Britain's GlaxoSmithKline, had delivered positive results after nearly a year of setbacks that left it lagging far behind its rivals.

Radio France Internationale

inkl

Read news from The Economist, FT, and more,
with one subscription

New Covid vaccine 100% effective against severe disease, data suggests

New Covid vaccine 100% effective against severe disease, data suggests

A Covid-19 vaccine that showed it is 100 per cent effective in preventing severe disease and hospitalisation in its trial data is seeking regulatory approval.

Evening Standard

Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data

Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are

Sanofi and GSK seek approval for Covid-19 vaccine

Sanofi and GSK seek approval for Covid-19 vaccine

The drugmakers hope to catch up with rivals after reporting positive results from late-stage clinical trials

The Guardian - UK

New Covid vaccine 100% effective against severe disease, manufacturers say

New Covid vaccine 100% effective against severe disease, manufacturers say

French pharmaceutical Sanofi and its British partner GlaxoSmithKline hope their vaccine will also be used as a booster

The Independent UK

The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings

The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours.

Hopeful Golden Cross Forms On Sanofi's Chart

Hopeful Golden Cross Forms On Sanofi's Chart

If history is any guide, there may be good fortune ahead for shares of Sanofi (NASDAQ:SNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Sanofi: Q4 Earnings Insights

Sanofi: Q4 Earnings Insights

Sanofi (NASDAQ:SNY) reported its Q4 earnings results on Friday, February 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures

Here's a roundup of top developments in the biotech space over the last 24 hours.

Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars

Sanofi SA's (NASDAQ: SNY)

A Preview Of Sanofi's Earnings

Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will likely report an Earnings Per Share (EPS) of $0.72.

What Does Sanofi's Debt Look Like?

Over the past three months, shares of Sanofi (NASDAQ:SNY) increased by 1.88%. Before we understand the importance of debt, let us look at how much debt Sanofi has.

Get all your
news in one place.

100's of premium titles.
One news app.

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have

1 … 5 6 7 8

People

John Vandermosten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Regeneron Pharmaceuticals Inc

GlaxoSmithKline

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

381,007 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play